Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.

Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ.

PLoS One. 2009;4(2):e4583. doi: 10.1371/journal.pone.0004583. Epub 2009 Feb 25.

2.

The molecular pathogenesis of the myelodysplastic syndromes.

Pellagatti A, Boultwood J.

Eur J Haematol. 2015 Jul;95(1):3-15. doi: 10.1111/ejh.12515. Epub 2015 Feb 20. Review.

PMID:
25645650
3.

Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Ebert BL.

Semin Oncol. 2011 Oct;38(5):621-6. doi: 10.1053/j.seminoncol.2011.04.010. Review.

4.

5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.

Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, Tibes R, Furge KA, Alberts AS.

Oncogene. 2009 Oct 1;28(39):3429-41. doi: 10.1038/onc.2009.207. Epub 2009 Jul 13. Review.

PMID:
19597464
5.

Deletions of chromosome 5 in malignant myeloid disorders.

Le Beau MM.

Cancer Surv. 1992;15:143-59. Review.

PMID:
1451109
6.

Myelodysplastic syndromes: an update on molecular pathology.

Tormo M, Marugán I, Calabuig M.

Clin Transl Oncol. 2010 Oct;12(10):652-61. doi: 10.1007/s12094-010-0574-9. Review.

PMID:
20947479
7.

Genetic deletions in AML and MDS.

Ebert BL.

Best Pract Res Clin Haematol. 2010 Dec;23(4):457-61. doi: 10.1016/j.beha.2010.09.006. Epub 2010 Nov 4. Review.

8.

Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

Ebert BL.

Leukemia. 2009 Jul;23(7):1252-6. doi: 10.1038/leu.2009.53. Epub 2009 Mar 26. Review.

PMID:
19322210
9.

Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

Nimer SD.

J Clin Oncol. 2006 Jun 1;24(16):2576-82. Review.

PMID:
16735711
10.
11.

5q-, twenty-five years later: a synopsis.

Van den Berghe H, Michaux L.

Cancer Genet Cytogenet. 1997 Mar;94(1):1-7. Review.

PMID:
9078284
12.

A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.

Voutsadakis IA, Cairoli A.

Leuk Lymphoma. 2012 May;53(5):779-88. doi: 10.3109/10428194.2011.623255. Epub 2011 Nov 25. Review.

PMID:
21955212
13.

Molecular analysis of the 5q- chromosome.

Nagarajan L.

Leuk Lymphoma. 1995 May;17(5-6):361-6. Review.

PMID:
7549826
14.

Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.

Olney HJ, Le Beau MM.

Leuk Res. 2007 Apr;31(4):427-34. Epub 2006 Dec 11. Review.

PMID:
17161457
15.

Current treatment options: impact of cytogenetics on the course of myelodysplasia.

Galili N, Cerny J, Raza A.

Curr Treat Options Oncol. 2007 Apr;8(2):117-28. Review.

PMID:
17634837
16.

[Progress of cytogenetic detection in myelodysplastic syndromes].

Zhou QB, Hu XM, Liu -, Ma R.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Dec;19(6):1536-40. Review. Chinese.

PMID:
22169320
17.

Molecular genetic aspects of myelodysplastic syndromes.

Bartram CR.

Hematol Oncol Clin North Am. 1992 Jun;6(3):557-70. Review.

PMID:
1613006
18.

5q- syndrome.

Boultwood J, Pellagatti A, Wainscoat JS.

Curr Pharm Des. 2012;18(22):3180-3. Review.

PMID:
22571696
Items per page

Supplemental Content

Write to the Help Desk